We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





New AI-Driven COVID-19 Testing Algorithm Could Lead to Fewer Infections

By LabMedica International staff writers
Posted on 25 Jan 2021
A new artificial intelligence (AI) algorithm could help leaders of governments and organizations make better informed decisions on how many symptomatic and asymptomatic individuals to test for COVID-19 with a limited supply of daily tests, and at what stage of the pandemic.

Simulated testing strategies of the AI model developed by researchers at Penn State’s College of Information Sciences and Technology (University Park, PA, USA) resulted in approximately 40% fewer infections. More...
Using an AI model known as Partially Observable Markov Decision Processes, the team developed a sequential policy for distributing tests among a population. Their model, called Design of Optimal COVID-19 Testing Oracle, or DOCTOR, was measured against other existing testing strategies used by governments and institutions. Many of these other strategies are static and non-adaptive, potentially causing significant shortcomings in their effectiveness in containing COVID-19.

In a two-phased approach, DOCTOR first suggests spending more effort in testing symptomatic individuals, allocating approximately 65% of its available testing kits for individuals presenting symptoms. Over time, as the number of symptomatic individuals diminishes due to these patients moving to quarantine or hospital settings, DOCTOR shifts its attention to asymptomatic testing, gradually increasing the number of testing kits allocated to asymptomatic individuals as decision points proceed. When applied in a simulation to the city of Santiago in Panama - a country with the world’s highest rate of COVID-19 infections per capita - the model’s testing strategy outperformed state-of-the-art baselines by achieving approximately 40% fewer COVID-19 infections. This illustrates the benefit of having an adaptive strategy, and even more so with new variants of the virus emerging, according to the researchers. The team’s research shows that the use of an AI-driven testing strategy for COVID-19 would be most beneficial when the pandemic spread is intermediate - meaning it’s not too severe and it’s not too slow. As COVID-19 is currently in an intermediate stage in many places worldwide, it is an optimal time for governments and institutions to consider an AI-driven testing strategy. Additionally, the model could be useful in guiding decision makers in the event of a future pandemic.

“There is a possibility that testing is still going to be a part of our COVID-19 prevention efforts in the next year,” said Amulya Yadav, PNC Technologies Career Development Assistant Professor at the College of IST. “Even if vaccines work on the new variants as well, I think there is going to be a difference or a divide between developed and underdeveloped countries and how quickly they are able to vaccinate their populations. So testing is going to be much more important.”

Related Links:
Penn State


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Acute lymphoblastic leukemia in children and young people requires careful relapse risk assessment as treatment expands beyond standard chemotherapy. (Image Credit: Shutterstock)

New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL

Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea

Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.